COVID-19 | Discover the latest peer-reviewed research articles from the Eastern Mediterranean Region
COVID-19 | Discover the latest peer-reviewed research articles from the Eastern Mediterranean Region
COVID-19 | Discover the latest publications published by WHO Regional Office for the Eastern Mediterranean
COVID-19 | Discover the latest publications published by WHO Regional Office for the Eastern Mediterranean

Virtual Health Sciences Library

  • Home
  • Search
  • Knowledge Base
  • Get a journal indexed in the Index Medicus
  • MyVHSL
  1. Home
  2. IMEMR
  3. Search Result
  4. Pegylated interferon and ribavirin for post liver transplant HCV recurrence

Pegylated interferon and ribavirin for post liver transplant HCV recurrence

Authors

Dilshad Akif
Shaikh Zayed Hospital ; , Department of Gastroenterology ;

Proceedings-Shaikh Zayed Postgrad. Med. Inst. 2015; 29 (1): 1-4
Proceedings-Shaikh Zayed Postgraduate Medical Institute
Journal Country: Pakistan
Indexing Status : In Process
Citation: Akif Dilshad , Pegylated interferon and ribavirin for post liver transplant HCV recurrence, Proceedings-Shaikh Zayed Postgrad. Med. Inst. 2015; 29 (1): 1-4

Abstract English

Pakistan has a very high HCV prevalence [1] with majority being genotype 3. A high number of patients with cirrhosis undergo liver transplantation. HCV recurrence following transplant is universal [2] . Interferon free therapy has recently become available and preliminary studies show 70% SVR in post transplant patients [3] . Since genotype 3 has a high response to pegylated Interferon 3, it remains a competitive agent Aims and Methods: The aim of this study was to determine the efficacy of pegylated interferon plus ribavirin in the treatment of recurrent hepatitis C following liver transplantation.15 patients with recurrent hepatitis C following liver transplantation were included in the study, 13 males and 2 females. Mean age was 52 years.13 had genotype 3 disease, one genotype 2 and one genotype 1.11 were living donor and 4 were cadaveric grafts.13 were on tacrolimus and MMF, one on tacrolimus alone and one on cyclosporine and MMF.6 patients were treated within 2 years of transplant and remaining 9 were treated 3-5 years after transplant. Liver biopsy was done prior to therapy in 6 patients. All patients received pegylated interferon a2a 180 g weekly plus ribavirin 15mg/kg daily for 48 weeks
Results: 14 out of 15 patients [93.3%] achieved SVR. This included all 13 Genotype 3 patients [100%] and the single genotype 2 patient. One patient, genotype 1, was nonresponder to treatment. Treatment was stopped at 22 and 36 weeks in 2 patients due to anaemia. Both achieved SVR.11 patients were administered erythropoietin for anemia.7 patients required ribavirin dose reduction for anemia, and achieved SVR despite dose reduction

Request full text

Subscribe to VHSL Newsletters

© 2020 WHO – EMRO